肠易激综合征患者的血清水平及 表达情况
The Serum Levels of and Expression in Patients with Irritable Bowel Syndrome.
作者信息
Hayatbakhsh Mohammad Mahdi, Gowhari Shabgah Arezoo, Pishgouyi Saeed, Tavakol Afshari Jalil, Zeidabadi Hadi, Mohammadi Mojgan
机构信息
Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology sciences, Kerman University of Medical Sciences, Kerman, Iran.
Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
出版信息
Rep Biochem Mol Biol. 2019 Apr;8(1):9-14.
BACKGROUND
Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by altered bowel habits and abdominal pain in the absence of a recognizable structural anomaly. The pathogenesis of IBS has been associated with inflammation and the expression of pro-inflammatory chemokines, such as CCL2 and CCL16. Our study aimed to investigate the relationship between the serum levels of CCL2 and CCL16 and IBS. Additionally, we examined how serum levels of these chemokines relate to IBS subtypes.
METHODS
Patients with IBS diagnosed according to the Rome III criteria participated in this study (n= 96). Healthy individuals with no history of allergic, autoimmune, chronic or active gastrointestinal infectious diseases were used as controls (n= 44). The serum levels of CCL2 and CCL16 was measured via enzyme-linked immunosorbent assay (ELISA).
RESULTS
A significant decrease in the serum levels of CCL16 and CCL2 was observed in the patients with IBS. Additionally, the serum levels of CCL16 in IBS patients with diarrhea (D-IBS) was significantly higher than those with the mixed IBS (M-IBS) subtype.
CONCLUSION
The significant increase in the serum levels of CCL-16 in patients with D-IBS compared to patients with M-IBS suggests that CCL-16 may be used as an immunological biomarker to differentiate between these two subtypes.
背景
肠易激综合征（IBS）是一种功能性胃肠疾病，其特征为排便习惯改变和腹痛，且无明显的结构异常。IBS的发病机制与炎症及促炎趋化因子如CCL2和CCL16的表达有关。我们的研究旨在调查CCL2和CCL16的血清水平与IBS之间的关系。此外，我们还研究了这些趋化因子的血清水平与IBS亚型的关系。
方法
根据罗马III标准诊断为IBS的患者参与了本研究（n = 96）。无过敏、自身免疫、慢性或活动性胃肠道传染病史的健康个体作为对照（n = 44）。通过酶联免疫吸附测定（ELISA）测量CCL2和CCL16的血清水平。
结果
IBS患者的CCL16和CCL2血清水平显著降低。此外，腹泻型IBS（D-IBS）患者的CCL16血清水平显著高于混合型IBS（M-IBS）亚型患者。
结论
与M-IBS患者相比，D-IBS患者的CCL-16血清水平显著升高，这表明CCL-16可作为一种免疫生物标志物来区分这两种亚型。
Zotero 插件